MA45130A - Polymorphes de n-[(3-fluoro-4-méthoxypyridin-2-yl)méthyl]-3-(méthoxyméthyl)-1-({4-[2-oxopyridin-1-yl)méthyl]phényl}méthyl)pyrazole-4-carboxamide utilisés comme inhibiteurs de la kallicréine - Google Patents

Polymorphes de n-[(3-fluoro-4-méthoxypyridin-2-yl)méthyl]-3-(méthoxyméthyl)-1-({4-[2-oxopyridin-1-yl)méthyl]phényl}méthyl)pyrazole-4-carboxamide utilisés comme inhibiteurs de la kallicréine

Info

Publication number
MA45130A
MA45130A MA045130A MA45130A MA45130A MA 45130 A MA45130 A MA 45130A MA 045130 A MA045130 A MA 045130A MA 45130 A MA45130 A MA 45130A MA 45130 A MA45130 A MA 45130A
Authority
MA
Morocco
Prior art keywords
methyl
phenyl
kallicrein
oxopyridin
methoxypyridin
Prior art date
Application number
MA045130A
Other languages
English (en)
Other versions
MA45130B1 (fr
Inventor
Haydn Beaton
David Malcolm Crowe
Hannah Joy Edwards
Nicholas James Griffiths-Haynes
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA45130A publication Critical patent/MA45130A/fr
Publication of MA45130B1 publication Critical patent/MA45130B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA45130A 2016-06-01 2017-06-01 Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein MA45130B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609607.5A GB201609607D0 (en) 2016-06-01 2016-06-01 Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
PCT/GB2017/051579 WO2017208005A1 (fr) 2016-06-01 2017-06-01 Polymorphes de n-[(3-fluoro-4-méthoxypyridin-2-yl)méthyl]-3-(méthoxyméthyl)-1-({4-[2-oxopyridin-1-yl)méthyl]phényl}méthyl)pyrazole-4-carboxamide utilisés comme inhibiteurs de la kallicréine

Publications (2)

Publication Number Publication Date
MA45130A true MA45130A (fr) 2019-04-10
MA45130B1 MA45130B1 (fr) 2022-10-31

Family

ID=56410856

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45130A MA45130B1 (fr) 2016-06-01 2017-06-01 Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein

Country Status (25)

Country Link
US (3) US11230537B2 (fr)
EP (2) EP4151630A1 (fr)
JP (2) JP6957516B2 (fr)
KR (1) KR102425918B1 (fr)
CN (1) CN109379891B (fr)
AU (1) AU2017273136B2 (fr)
BR (1) BR112018073521B1 (fr)
CA (1) CA3025720A1 (fr)
DK (1) DK3464265T3 (fr)
ES (1) ES2927779T3 (fr)
GB (1) GB201609607D0 (fr)
HR (1) HRP20221019T1 (fr)
HU (1) HUE059165T2 (fr)
IL (1) IL263222B (fr)
LT (1) LT3464265T (fr)
MA (1) MA45130B1 (fr)
MD (1) MD3464265T2 (fr)
MX (1) MX2018014700A (fr)
PL (1) PL3464265T3 (fr)
PT (1) PT3464265T (fr)
RS (1) RS63604B1 (fr)
RU (1) RU2756273C2 (fr)
SI (1) SI3464265T1 (fr)
WO (1) WO2017208005A1 (fr)
ZA (1) ZA201808638B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
BR112018074395A2 (pt) 2016-05-31 2019-03-06 Kalvista Pharmaceuticals Limited derivados de pirazol como inibidores de calicreína plasmática
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
LT3716952T (lt) 2017-11-29 2022-04-11 Kalvista Pharmaceuticals Limited Vaisto formos, apimančios plazmos kalikreino inhibitorių
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CA3093802A1 (fr) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Imidazopyridines substituees en tant qu'inhibiteurs de la kallicreine plasmatique et leurs utilisations
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
WO2021055589A1 (fr) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Inhibiteurs hétéroaryles de la kallicréine plasmatique
WO2021055621A1 (fr) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Inhibiteurs de la kallicréine plasmatique et leurs utilisations
CN111875557B (zh) * 2020-08-19 2023-06-02 南通大学 一种噻唑类衍生物及其合成方法
WO2022084693A1 (fr) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
EP4291186A1 (fr) * 2021-02-09 2023-12-20 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2024180100A1 (fr) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited Nouvelle forme solide d'un inhibiteur de la kallicréine plasmatique

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
WO2000062778A1 (fr) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Inhibiteurs cycliques de proteine tyrosine kinase
AU784946B2 (en) 1999-12-08 2006-08-03 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
PE20040600A1 (es) 2002-04-26 2004-09-15 Lilly Co Eli Derivados de triazol como antagonistas del receptor de taquicinina
EP1426364A1 (fr) 2002-12-04 2004-06-09 Aventis Pharma Deutschland GmbH Dérivés d'imidazole comme inhibiteurs du facteur Xa
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US20040192728A1 (en) 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
EP1568698A1 (fr) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Dérivés de pyrrole en tant qu'inhibiteurs du facteur xa
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006025714A1 (fr) 2004-09-03 2006-03-09 Yuhan Corporation Derives pyrrolo[3,2-c]pyridine et procedes de preparation de ces derniers
WO2006091459A2 (fr) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions et methodes permettant de traiter la permeabilite vasculaire
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
US20090041829A1 (en) 2005-04-28 2009-02-12 Galenica Technology Ab Pharmaceutical dosage forms comprising a lipid phase
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
JP2009501236A (ja) 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
GB0606876D0 (en) 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
US20070258976A1 (en) 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
CA2655675A1 (fr) 2006-07-06 2008-01-10 Glaxo Group Limited N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation
EP2051707B1 (fr) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibiteurs de kallicréine plasmatique
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
RU2485114C2 (ru) 2006-12-29 2013-06-20 Эбботт Гмбх Унд Ко.Кг Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
US20100119512A1 (en) 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
CA2680312A1 (fr) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Inhibiteurs de metalloprotease contenant une fraction heterocyclique
CN101646656B (zh) 2007-03-30 2013-08-14 塞诺菲-安万特股份有限公司 作为pgds抑制剂的嘧啶酰肼化合物
JP2010523524A (ja) 2007-04-03 2010-07-15 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのイミダゾリジンカルボキサミド誘導体
BRPI0814314A2 (pt) 2007-07-26 2015-05-26 Syngenta Participations Ag Microbiocidas
AU2008288897A1 (en) 2007-08-22 2009-02-26 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2009083553A1 (fr) 2007-12-31 2009-07-09 Rheoscience A/S Composés azines en tant qu'activateurs de glucokinase
US8658685B2 (en) 2008-01-31 2014-02-25 Activesite Pharmaceuticals, Inc. Methods for treatment of kallikrein-related disorders
WO2009106980A2 (fr) 2008-02-29 2009-09-03 Pfizer Inc. Dérivés d'indazole
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
SI2308838T1 (sl) 2008-07-08 2016-09-30 Daiichi Sankyo Company, Limited Dušik vsebujoča aromatska heterociklična spojina
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP2013515000A (ja) 2009-12-18 2013-05-02 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬のプロドラッグ
JP2011157349A (ja) 2010-01-07 2011-08-18 Daiichi Sankyo Co Ltd 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
BR112012019042A8 (pt) 2010-01-28 2017-12-26 The Medicines Company Leipzig Gmbh compostos inibidores de serina protease tipo tripsina, seu uso, e seus processos de preparação
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (fr) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Inhibiteurs de la sérine protéase
WO2012009009A2 (fr) 2010-07-14 2012-01-19 Addex Pharma S.A. Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2458315B1 (fr) 2010-11-25 2017-01-04 Balcke-Dürr GmbH Echangeur thermique régénératif doté d'un joint de rotor forcé
WO2012142308A1 (fr) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de la kallicréine plasmatique
WO2012170020A1 (fr) 2011-06-08 2012-12-13 Micro Motion, Inc. Procédé et appareil destinés à déterminer et commander une pression statique de fluide dans un débitmètre vibratoire
WO2012174362A1 (fr) 2011-06-17 2012-12-20 Research Triangle Institute Dérivés de pyrazole utilisés en tant qu'antagonistes du récepteur de type 1 des cannabinoïdes
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
EP2760829B1 (fr) 2011-09-27 2016-05-18 Bristol-Myers Squibb Company Dérivés de pyrrolinone-carboxamide utiles comme inhibiteurs de lipase endothéliale
WO2013049096A1 (fr) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale
WO2013111108A1 (fr) * 2012-01-27 2013-08-01 Novartis Ag Dérivés hétéroarylcarboxamide à 5 chaînons comme inhibiteurs de la kallikréine plasmatique
EP2807156A1 (fr) 2012-01-27 2014-12-03 Novartis AG Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la kallicréine plasmatique
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
US9846160B2 (en) 2012-02-27 2017-12-19 Board Of Regents, The University Of Texas Systems Ganglioside GD2 as a marker and target on cancer stem cells
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
KR20150103285A (ko) 2013-01-08 2015-09-09 사피라 파르마슈티칼즈 게엠베하 피리미돈 유도체 및 바이러스 질환의 치료, 개선 또는 예방에서의 이의 용도
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PH12015501492A1 (en) * 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
ES2692408T3 (es) 2013-01-20 2018-12-03 Dyax Corp. Evaluación y tratamiento de trastornos mediados por bradiquinina
RU2019101889A (ru) 2013-03-15 2019-03-28 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
PL2999697T3 (pl) * 2013-05-23 2017-09-29 Kalvista Pharmaceuticals Limited Pochodne heterocykliczne
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
WO2015022546A1 (fr) 2013-08-14 2015-02-19 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
EA032713B1 (ru) 2013-12-30 2019-07-31 Лайфсай Фармасьютикалс, Инк. Терапевтические ингибирующие соединения
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
MX2016011468A (es) 2014-03-07 2017-01-23 Biocryst Pharm Inc Inhibidores de calicreína plasmática humana.
WO2015171526A2 (fr) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Composés de pyrazolopyridine tricycliques
WO2015171527A1 (fr) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine, pyrazolopyrimidine et composés apparentés
AU2015289643B2 (en) 2014-07-16 2020-10-22 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
AU2015305214B2 (en) 2014-08-22 2020-04-23 Biocryst Pharmaceuticals, Inc. Compositions and uses of amidine derivatives
WO2016044662A1 (fr) 2014-09-17 2016-03-24 Verseon Corporation Composés de pyridone substituée par pyrazolyl en tant qu'inhibiteurs de sérine protéase
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
EP3261639B1 (fr) 2015-02-27 2022-08-24 Verseon International Corporation Composés pyrazole substitués à utiliser en tant qu'inhibiteurs de sérine protéase
US10981893B2 (en) 2015-07-01 2021-04-20 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2017001936A2 (fr) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
EP3368524B1 (fr) 2015-10-27 2021-08-18 Boehringer Ingelheim International GmbH Utilisation de dérivés hétéroarylcarboxamides comme inhibiteurs de la kallicréine plasmatique
US10399961B2 (en) 2015-10-27 2019-09-03 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
BR112018074395A2 (pt) 2016-05-31 2019-03-06 Kalvista Pharmaceuticals Limited derivados de pirazol como inibidores de calicreína plasmática
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物
GB201713660D0 (en) 2017-08-25 2017-10-11 Kalvista Pharmaceuticals Ltd Pharmaceutical compositions
GB201721515D0 (en) 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
WO2019106359A1 (fr) 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Inhibiteurs d'enzymes
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
CN114269431A (zh) 2019-08-21 2022-04-01 卡尔维斯塔制药有限公司 酶抑制剂
WO2021032936A1 (fr) 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Inhibiteurs d'enzymes
AU2019462140A1 (en) 2019-08-21 2022-02-24 Kalvista Pharmaceuticals Limited Enzyme inhibitors
EP4017850A1 (fr) 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Inhibiteurs d'enzyme
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity

Also Published As

Publication number Publication date
US20240199573A1 (en) 2024-06-20
CA3025720A1 (fr) 2017-12-07
JP7383676B2 (ja) 2023-11-20
EP3464265B1 (fr) 2022-07-13
EP4151630A1 (fr) 2023-03-22
CN109379891B (zh) 2022-04-26
RS63604B1 (sr) 2022-10-31
PL3464265T3 (pl) 2022-11-07
AU2017273136B2 (en) 2021-07-08
HUE059165T2 (hu) 2022-10-28
LT3464265T (lt) 2022-11-10
MA45130B1 (fr) 2022-10-31
DK3464265T3 (da) 2022-08-22
IL263222A (en) 2018-12-31
JP2019517463A (ja) 2019-06-24
AU2017273136A1 (en) 2018-11-29
RU2018139276A3 (fr) 2020-10-07
BR112018073521B1 (pt) 2024-02-06
CN109379891A (zh) 2019-02-22
MX2018014700A (es) 2019-02-28
JP2022003083A (ja) 2022-01-11
WO2017208005A1 (fr) 2017-12-07
PT3464265T (pt) 2022-10-20
EP3464265A1 (fr) 2019-04-10
JP6957516B2 (ja) 2021-11-02
BR112018073521A2 (pt) 2019-03-19
KR20190033485A (ko) 2019-03-29
ES2927779T3 (es) 2022-11-10
KR102425918B1 (ko) 2022-07-26
GB201609607D0 (en) 2016-07-13
US20200317633A1 (en) 2020-10-08
RU2756273C2 (ru) 2021-09-29
SI3464265T1 (sl) 2022-09-30
US20220041571A1 (en) 2022-02-10
US11739068B2 (en) 2023-08-29
RU2018139276A (ru) 2020-07-10
ZA201808638B (en) 2019-09-25
US11230537B2 (en) 2022-01-25
HRP20221019T1 (hr) 2022-11-11
MD3464265T2 (ro) 2022-12-31
IL263222B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
MA45130A (fr) Polymorphes de n-[(3-fluoro-4-méthoxypyridin-2-yl)méthyl]-3-(méthoxyméthyl)-1-({4-[2-oxopyridin-1-yl)méthyl]phényl}méthyl)pyrazole-4-carboxamide utilisés comme inhibiteurs de la kallicréine
MA50205A (fr) Formulation de nicotine
GB201609519D0 (en) Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
FR24C1009I1 (fr) Composés utilisés comme inhibiteurs de kinase
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
GB201609603D0 (en) Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
AR100251A1 (es) Inhibidores de la dematilasa-1 especifica de lisina
EA201790715A1 (ru) Новые соединения
DK3724190T3 (da) Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
EA202091500A1 (ru) Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
MA41014A (fr) Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MA49401A (fr) Inhibiteurs de la kinase alk2 contenant de l'imidazole
BR112018002071A2 (pt) compostos heteroarílicos ou arílicos fundidos bicíclicos
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
MA45656A (fr) Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
DK3286176T3 (da) Krystallinske former af 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleat
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
DK3670499T3 (da) Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
MA42655A (fr) Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer
DK3458467T3 (da) Fremgangsmåde til 6,7-alfa-epoxidering af steroid-4,6-diener
DK3452484T3 (da) Visse protein-kinase-inhibitorer